Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus

BACKGROUND: Ipragliflozin, a sodium-glucose transporter 2 inhibitor, was administered to patients with type 2 diabetes mellitus for 24 weeks to evaluate its effect on glycemic control and body composition. METHODS: This was an investigator-initiated multicenter prospective intervention study in whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawata, Takehiro, Iizuka, Takashi, Iemitsu, Kotaro, Takihata, Masahiro, Takai, Masahiko, Nakajima, Shigeru, Minami, Nobuaki, Umezawa, Shinichi, Kanamori, Akira, Takeda, Hiroshi, Ito, Shogo, Kikuchi, Taisuke, Amemiya, Hikaru, Kaneshiro, Mizuki, Mokubo, Atsuko, Takuma, Tetsuo, Machimura, Hideo, Tanaka, Keiji, Asakura, Taro, Kubota, Akira, Aoyanagi, Sachio, Hoshino, Kazuhiko, Ishikawa, Masashi, Matsuzawa, Yoko, Obana, Mitsuo, Sasai, Nobuo, Kaneshige, Hideaki, Minagawa, Fuyuki, Saito, Tatsuya, Shinoda, Kazuaki, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458656/
https://www.ncbi.nlm.nih.gov/pubmed/28611859
http://dx.doi.org/10.14740/jocmr3038w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458656/
https://www.ncbi.nlm.nih.gov/pubmed/28611859
http://dx.doi.org/10.14740/jocmr3038w

Ejemplares similares